Who pays for the research and development of new medicines? What medicines get most of the research and development money? These questions have been highlighted in the recent controversy regarding the cost of anti-HIV drugs in South Africa. Private companies seeking to maximise profits, spend on medicines that can be sold to richer, developed nations. The cost of this 'economic rationale' is borne by the people of developing and poor nations.Illnesses like malaria get ignored and millions are spent on research on drugs which promise to cure the ailments of affluence.
|Pharmaceutical companies' claims of investing in research are disputable|
|The research and development cost of an average new drug is only US $57-71 million|
|Only 22 per cent of the new drugs in the last two decades were medicallyy innovative|
|Some of the top pharmaceutical companies spent twice the amount on advertisement than they did on research and development|
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.